Current Report Filing (8-k)
May 24 2022 - 8:06AM
Edgar (US Regulatory)
0001709401
false
0001709401
2022-05-20
2022-05-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 20, 2022
RUBIUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38586 |
|
46-2688109 |
(State or other jurisdiction of Incorporation)
|
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
399 Binney Street, Suite 300 Cambridge, MA | |
02139 |
(Address of registrant’s principal executive office) | |
(Zip code) |
(617) 679-9600
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class |
Trading symbol(s) |
Name
of each exchange on which
registered |
Common Stock, par value $0.001 per share |
RUBY |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.02. Termination
of a Material Definitive Agreement.
On May 24, 2022, Rubius
Therapeutics, Inc. (the “Company”) issued a press release announcing that Noubar Afeyan, Ph.D., has been appointed
as chairman of its board of directors, succeeding David Epstein in such role. Mr. Epstein will remain a member of the board of directors
of the Company. In connection with this leadership transition, on May 20, 2022, the Company terminated the Second Amended and Restated
Chairman Agreement, dated June 21, 2018, by and between the Company and Mr. Epstein.
Item 7.01. Regulation
FD Disclosure.
A copy of the press release
referenced above is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information under
this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 24, 2022 |
RUBIUS THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Pablo J. Cagnoni |
|
|
Pablo J. Cagnoni |
|
|
Chief Executive Officer |
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Sep 2023 to Sep 2024